John Tilton is CCO at Biohaven Pharmaceutical Holding Co Ltd. (BHVN). They have made 5 open-market trades across 1 company since 2017, most recently 2022-10-03.
CIK 0001704251
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BHVN | 1,614 | $17K |
Shares reported on the most recent Form 4, priced at the 2022-10-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BHVN | SELL | 2020-06-10 | 2020-06-12 | $67.38 | $7.0M | +7.9% | +7.2% | -5.2% |
| BHVN | SELL | 2019-03-12 | 2019-03-14 | $50.11 | $501K | +5.2% | +19.2% | +24.4% |
| BHVN | SELL | 2019-01-10 | 2019-01-14 | $37.67 | $396K | +0.9% | +24.6% | +68.7% |
| BHVN | SELL | 2017-11-01 | 2017-11-02 | $29.25 | $878K | -15.5% | -26.6% | +19.7% |
| BHVN | SELL | 2017-11-01 | 2017-11-02 | $29.25 | $878K | -15.5% | -26.6% | +19.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.